SACITUZUMAB GOVITECAN (IMMU-132 / HRS7-SN38) Clinical Trials

TrialTitleStudy Record DetailPhaseSponsor/ Collaborator
Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast CancerNCT02574455IImmunomedics, Inc.
Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast CancerNCT02161679IIImmunomedics, Inc.
Phase I/II Study of IMMU-132 in Patients With Epithelial CancersNCT01631552I & IIImmunomedics, Inc.

Last Editorial Review: November 12, 2016